Short Interest in Lisata Therapeutics, Inc. (NASDAQ:LSTA) Declines By 21.2%

Lisata Therapeutics, Inc. (NASDAQ:LSTA) saw a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 31,600 shares, a decrease of 21.2% from the February 28th total of 40,100 shares. Based on an average trading volume of 39,500 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.5% of the company’s shares are sold short.

Lisata Therapeutics Stock Performance

Shares of NASDAQ:LSTA traded down $0.09 during midday trading on Wednesday, hitting $2.07. 16,131 shares of the company’s stock traded hands, compared to its average volume of 20,816. The firm’s fifty day moving average price is $2.44 and its two-hundred day moving average price is $2.81. Lisata Therapeutics has a twelve month low of $2.05 and a twelve month high of $4.20. The company has a market cap of $17.84 million, a PE ratio of -0.82 and a beta of 1.16.

Lisata Therapeutics (NASDAQ:LSTA) last issued its earnings results on Thursday, February 27th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.21. The company had revenue of $1.00 million during the quarter. As a group, equities research analysts anticipate that Lisata Therapeutics will post -2.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lisata Therapeutics stock. Citadel Advisors LLC acquired a new stake in Lisata Therapeutics, Inc. (NASDAQ:LSTA) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 23,273 shares of the company’s stock, valued at approximately $69,000. Citadel Advisors LLC owned about 0.28% of Lisata Therapeutics at the end of the most recent reporting period. Institutional investors own 8.94% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Lisata Therapeutics in a report on Wednesday, December 11th.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.